Literature DB >> 21625975

Caspase- and p38-MAPK-dependent induction of apoptosis in A549 lung cancer cells by Newcastle disease virus.

Jianchun Bian1, Kai Wang, Xiangang Kong, Huairan Liu, Fei Chen, Maozhi Hu, Xiaorong Zhang, Xinan Jiao, Baoxue Ge, Yantao Wu, Songshu Meng.   

Abstract

Newcastle disease virus (NDV) has a potential oncolytic effect due to its ability to induce apoptosis in tumor cells. However, previous studies have indicated discrepancies regarding the apoptosis signaling pathways induced by NDV in tumor cells. Here, we show that NDV infection induces simultaneous activation of intrinsic and extrinsic death pathways in A549 human lung cancer cells. In contrast, endoplasmic reticulum (ER) stress is not activated in NDV-induced apoptosis. We demonstrate for the first time that mitogen-activated protein kinase (MAPK) pathways are activated in NDV-infected A549 cells, and p38 MAPK is involved in NDV-induced cell death. Together, our findings provide novel insights into the underlying mechanisms by which NDV induces apoptosis in tumor cells.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21625975     DOI: 10.1007/s00705-011-0987-y

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  34 in total

1.  Antineoplastic activity of Newcastle disease virus strain D90 in oral squamous cell carcinoma.

Authors:  Chun-Xiao Zhang; Long-Wei Ye; Ying Liu; Xiao-Ya Xu; Dan-Rui Li; Yan-Qing Yang; Lu-Lu Sun; Jie Yuan
Journal:  Tumour Biol       Date:  2015-04-16

2.  Oncolytic Newcastle disease virus induces autophagy-dependent immunogenic cell death in lung cancer cells.

Authors:  Tian Ye; Ke Jiang; Liwen Wei; Martin P Barr; Qing Xu; Guirong Zhang; Chan Ding; Songshu Meng; Haozhe Piao
Journal:  Am J Cancer Res       Date:  2018-08-01       Impact factor: 6.166

3.  Human renal carcinoma cells respond to Newcastle disease virus infection through activation of the p38 MAPK/NF-κB/IκBα pathway.

Authors:  Wei-Choong Ch'ng; Noraini Abd-Aziz; Meng-Hua Ong; Eric J Stanbridge; Norazizah Shafee
Journal:  Cell Oncol (Dordr)       Date:  2015-05-01       Impact factor: 6.730

Review 4.  Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions.

Authors:  Dmitriy Zamarin; Peter Palese
Journal:  Future Microbiol       Date:  2012-03       Impact factor: 3.165

5.  Molecular characterization of an apoptotic strain of Newcastle disease virus isolated from an outbreak in India.

Authors:  U Kumar; S Kumar
Journal:  Cancer Gene Ther       Date:  2015-08-07       Impact factor: 5.987

Review 6.  The therapeutic effect of death: Newcastle disease virus and its antitumor potential.

Authors:  Sara Cuadrado-Castano; Maria T Sanchez-Aparicio; Adolfo García-Sastre; Enrique Villar
Journal:  Virus Res       Date:  2015-07-26       Impact factor: 3.303

7.  Interleukin-22 protects rat PC12 pheochromocytoma cells from serum deprivation-induced cell death.

Authors:  Yongchun Liu; Wenyan Pan; Shengmei Yang; Xiaoying Wu; Jianfu Wu; Jun Ma; Zengqiang Yuan; Songshu Meng
Journal:  Mol Cell Biochem       Date:  2012-09-16       Impact factor: 3.396

8.  Oncolytic newcastle disease virus triggers cell death of lung cancer spheroids and is enhanced by pharmacological inhibition of autophagy.

Authors:  Lulu Hu; Sulan Sun; Tianpeng Wang; Yingchun Li; Ke Jiang; Guibin Lin; Yan Ma; Martin P Barr; Fei Song; Guirong Zhang; Songshu Meng
Journal:  Am J Cancer Res       Date:  2015-11-15       Impact factor: 6.166

9.  (E)-2,4-bis(p-hydroxyphenyl)-2-butenal has an antiproliferative effect on NSCLC cells induced by p38 MAPK-mediated suppression of NF-κB and up-regulation of TNFRSF10B (DR5).

Authors:  Pushpa Saranya Kollipara; Heon Sang Jeong; Sang Bae Han; Jin Tae Hong
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

10.  MicroRNA-204 plays a role as a tumor suppressor in Newcastle disease virus-induced oncolysis in lung cancer A549 cells.

Authors:  Ying Liang; Wen-Yu Tian; Juan-Juan Huang; Ling-Xi Gao; Xiao-Hui Fan
Journal:  Oncol Lett       Date:  2021-04-21       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.